WorldPharmaNews
Search ...
Home
Business
Research
Events
Regulatory
GSK - one of the world's leading research-based pharmaceutical and healthcare companies - is committed to improving the quality of human life by enabling people to do more, feel better and live longer.
www.gsk.com
GlaxoSmithKline RSS Channel
Filters
Display #
5
10
15
20
25
30
50
100
All
Filter
List of articles in category GlaxoSmithKline
Title
Published Date
GSK and Save the Children launch $1 million award to discover new healthcare innovations for reducing child deaths
30 June 2013
GSK and Save the Children form unique partnership to save the lives of one million children
14 May 2013
Funding boost for GSK's open innovation research into diseases affecting the developing world
05 May 2013
$500,000 endowment gift from the GlaxoSmithKline Foundation
18 March 2013
ViiV Healthcare announces FDA priority review designation for dolutegravir
17 February 2013
GSK response to news article in The Guardian on UK legal proceedings related to Avandia
30 January 2013
GSK forms partnership with Vodafone to help increase childhood vaccination in Mozambique
11 December 2012
GSK welcomes the publication of the 2012 Access to Medicines Index
03 December 2012
GSK announces start of Phase lll programme for mepolizumab in severe refractory asthma
29 October 2012
Millions of children in Pakistan to be protected against pneumococcal disease with GSK's Synflorix
09 October 2012
Start
Prev
2
3
4
5
6
7
8
9
10
11
Next
End
Business & Industry
Valneva switches focus to bilateral discussions to supply its inactivated, adjuvanted COVID-19 vaccine candidate VLA2001
Pfizer and BioNTech to supply the European Union with 100 million additional doses of COMIRNATY®
Amgen successfully completes acquisition of Five Prime Therapeutics
GSK and Vir Biotechnology announce EMA review of dual-action monoclonal antibody VIR-7831 for the early treatment of COVID-19
Phase III prevention trial showed subcutaneous administration of investigational antibody cocktail casirivimab and imdevimab reduced risk of symptomatic COVID-19 infections by 81%
Research & Development
Differing immune responses discovered in asymptomatic cases vs those with severe COVID-19
Patients who are obese or overweight are at risk for a more severe course of COVID-19
New COVID-19 vaccine may offer broad protection from coronaviruses
SARS-CoV-2: New findings on the persistence of neutralizing antibodies
Massive fragment screen points way to new SARS-CoV-2 inhibitors
B.1.1.7. variant more transmissible, does not increase severity, Lancet studies suggest
COVID-19 causes 'unexpected' cellular response in the lungs
Conferences & Events
Scientists urge for investment now in highly potent vaccines to prevent the next pandemic
CPhI Worldwide to return in 2021
Reuters Events' Cell & Gene Therapy USA
Total health: Build a better healthcare system
Don't fall for the 'next best action' trap
Locking down shape-shifting spike protein aids development of COVID-19 vaccine
COVID-19 vaccine innovation could dramatically speed up worldwide production
Regulatory Affairs
FDA revokes emergency use authorization for monoclonal antibody Bamlanivimab
Joint CDC and FDA statement on Johnson & Johnson COVID-19 vaccine
AstraZeneca's COVID-19 vaccine: EMA finds possible link to very rare cases of unusual blood clots with low blood platelets
Increase in vaccine manufacturing capacity and supply for COVID-19 vaccines from AstraZeneca, BioNTech/Pfizer and Moderna
EMA's safety committee continues investigation of COVID-19 Vaccine AstraZeneca and thromboembolic events
You are here:
Home
GlaxoSmithKline
GSK and Vir Biotechnology announce EMA review of dual-action monoclonal antibody VIR-7831 for the early treatment of COVID-19